JP7337086B2 - スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 - Google Patents

スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 Download PDF

Info

Publication number
JP7337086B2
JP7337086B2 JP2020550712A JP2020550712A JP7337086B2 JP 7337086 B2 JP7337086 B2 JP 7337086B2 JP 2020550712 A JP2020550712 A JP 2020550712A JP 2020550712 A JP2020550712 A JP 2020550712A JP 7337086 B2 JP7337086 B2 JP 7337086B2
Authority
JP
Japan
Prior art keywords
purin
fluoro
compound
mmol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550712A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518400A (ja
JP2021518400A5 (https=
Inventor
ジェフリー シャバーリ，
ディラン ブラッドリー イングランド，
ケネス エム． ギグスタッド，
アレクサンドラ イー． ゴールド，
ポール グリーンスパン，
ヨンボ フー，
シー－チュン ファン，
スティーブン ポール ラングストン，
尋丈 水谷
ジャン シー，
シュテファン ヴィスコシル，
へ シュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2021518400A publication Critical patent/JP2021518400A/ja
Publication of JP2021518400A5 publication Critical patent/JP2021518400A5/ja
Application granted granted Critical
Publication of JP7337086B2 publication Critical patent/JP7337086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020550712A 2018-03-23 2019-03-22 スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法 Active JP7337086B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647227P 2018-03-23 2018-03-23
US62/647,227 2018-03-23
US201962821831P 2019-03-21 2019-03-21
US62/821,831 2019-03-21
PCT/IB2019/052364 WO2019180683A1 (en) 2018-03-23 2019-03-22 Sting modulator compounds with sulfamate linkages, and methods of making and using

Publications (3)

Publication Number Publication Date
JP2021518400A JP2021518400A (ja) 2021-08-02
JP2021518400A5 JP2021518400A5 (https=) 2022-03-29
JP7337086B2 true JP7337086B2 (ja) 2023-09-01

Family

ID=66397323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550712A Active JP7337086B2 (ja) 2018-03-23 2019-03-22 スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法

Country Status (4)

Country Link
US (2) US20210015915A1 (https=)
EP (2) EP4242212A3 (https=)
JP (1) JP7337086B2 (https=)
WO (1) WO2019180683A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
KR20230106665A (ko) * 2020-11-11 2023-07-13 바이오젠 엠에이 인코포레이티드 올리고뉴클레오티드, 시약, 및 그의 제조 방법
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
JP2017518302A (ja) 2014-06-04 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
WO2017161349A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
JP2017518302A (ja) 2014-06-04 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
WO2016096174A1 (en) 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
WO2017161349A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2019118839A1 (en) 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists

Also Published As

Publication number Publication date
WO2019180683A1 (en) 2019-09-26
EP4242212A2 (en) 2023-09-13
EP4242212A3 (en) 2023-11-15
JP2021518400A (ja) 2021-08-02
US20250262298A1 (en) 2025-08-21
EP3768685A1 (en) 2021-01-27
US20210015915A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7337086B2 (ja) スルファメート結合を有するｓｔｉｎｇモジュレーター化合物、及び製造及び使用の方法
US12054512B2 (en) Sting modulator compounds, and methods of making and using
JP7792036B2 (ja) Ｍｃｌ－１阻害剤
TW202513571A (zh) 吡啶并[4,3-d]嘧啶化合物
CN102711766B (zh) N-9-取代的嘌呤化合物、组合物和使用方法
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
TWI784213B (zh) 雜環化合物
US9663525B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TW202332429A (zh) 治療性化合物及其使用方法
TW201825509A (zh) 環狀二核苷酸
US10865208B2 (en) ATG7 inhibitors and the uses thereof
AU2024317622A1 (en) Substitued bicyclic heterocyclic yap-tead and/or taz-tead inhibitors
RU2857665C2 (ru) Соединения пиридо[4,3-d]пиримидина
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
KR20260019509A (ko) Gpr68 조절 활성을 갖는 이환식 헤테로아릴아미드
JP2026505789A (ja) がん及びてんかんの治療に使用するための縮合ベンゾアゼピン誘導体
HK40038496B (en) Mcl-1 inhibitors
HK1176556B (en) N-9-substituted purine compounds, compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230822

R150 Certificate of patent or registration of utility model

Ref document number: 7337086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150